Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. The company was incorporated in 2010 and is based in Redwood City, California.

Coherus BioSciences Inc.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Coherus Biosciences today and set a price target of $7.00. According to TipRanks, T...

H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Coherus Biosciences (CHRS – Research Report), EDAP TMS (EDAP – Re...

Current Quarter	$-0.35	Next Quarter	$NA
Current Year	$-1.55	Next Year	$-0.83
QoQ Growth	NaN%	YoY Growth	+46.5%
3Y EPS CAGR	+27.4%	Target Price	$4.51
Consensus	Buy	Upside	+288.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CHRS	$1.16	+5.45%	881.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CHRS	$1.16	+5.5%	881.21K
3
4
5
6

CHRS

CHRS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Coherus BioSciences Inc. Data in Excel

Get Coherus BioSciences Inc. Data in Excel